1. Home
  2. BRN vs INAB Comparison

BRN vs INAB Comparison

Compare BRN & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Barnwell Industries Inc.

BRN

Barnwell Industries Inc.

HOLD

Current Price

$0.96

Market Cap

14.8M

Sector

Energy

ML Signal

HOLD

Logo IN8bio Inc.

INAB

IN8bio Inc.

HOLD

Current Price

$1.10

Market Cap

13.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRN
INAB
Founded
1956
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.8M
13.7M
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
BRN
INAB
Price
$0.96
$1.10
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
43.4K
71.7K
Earning Date
05-14-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$13,697,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.91
$0.88
52 Week High
$1.40
$2.73

Technical Indicators

Market Signals
Indicator
BRN
INAB
Relative Strength Index (RSI) 45.20 52.20
Support Level $0.93 $1.17
Resistance Level $1.00 $1.50
Average True Range (ATR) 0.04 0.10
MACD 0.00 0.02
Stochastic Oscillator 51.45 73.81

Price Performance

Historical Comparison
BRN
INAB

About BRN Barnwell Industries Inc.

Barnwell Industries Inc is an oil and gas company engaged in the acquisition, development, production, and sale of crude oil and natural gas. The Company operates through two segments: the Oil and Natural Gas segment, which focuses on oil and natural gas development, production, acquisitions, and sales in the United States and Canada; and the Land Investment segment, which owns leasehold land interests in Hawaii. The Company generates the majority of its revenue from the Oil and Natural Gas segment. The company operates in two geographic regions, the United States and Canada, with Canada contributing the majority of revenue.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

Share on Social Networks: